Nimbus Therapeutics Raises $210 Million for Small Molecule Drug Discovery
Related Articles (6)
Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise
The Boston biotech has sold two experimental drugs — a liver disease medicine and a TYK2 inhibitor — to Gilead and Takeda respectively.
Nimbus Therapeutics raises $210 million in fundraising round
The Boston-based biotech will work on new ‘small molecule’ drugs to combat cancer and other ailments.